Dear Colleague,

I am thrilled to be re-uniting the iPSC community once again at the new and improved 3rd Annual iPSC Derived Cell Therapies Summit, returning to Boston this October. With a speaker faculty of 86% new speakers and a brand new section to the agenda dedicated to navigating financial uncertainty and regulatory expectations, this is not to be missed. In addition, this is the largest meeting dedicated to iPSC drug development and a must-attend to accelerate your clinical proof of concept today! As biopharma face rocky times in terms of investment and funding, it has never been more business-critical to unite the iPSC field at this summit.

Be the first to see the expert speaker faculty and full program here.

Boasting novel insights from 30+ expert speakers, don’t miss out on clinical data from companies trailblazing iPSC-derived therapies to the clinic including Century Therapeutics, NIH and Heartseed Inc.

No matter your stage of therapeutic development, this flagship meeting will provide you with the expertise to take your pipeline forward!

Discover the refined Regulatory & Early Clinical Development track, guaranteed to inform your clinical translational strategy with exclusive sessions dedicated to streamlining manufacturing efficiency, benchmarking regulatory requirements, and tackling funding considerations. Additionally, the Discovery and Translation track will unite biopharma to dive deep into the technicalities of genomic stability and downstream effects of gene editing, formulation, and delivery to improve in vivo survivability and differentiation to enhance the safety and quality of your product.

A sneak peek of some of the new speakers sharing their experiences include:

• Kapil Bharti, Senior Investigator, NIH
• Michael Naso, Vice President, Century Therapeutics
• Irina Klimanskaya, Senior Director, Translational Science & Development, Astellas Institute for Regenerative Medicine
• Pinky Doshi, Vice President, Regulatory Affairs, Shoreline Biosciences
• Kevin D’Amour, Chief Scientific Officer​​​​, Stemson Therapeutics
• Dan Kemp, Chief Executive Officer, ThyasEvade

View the official event guide and full speaker line-up here.

With focused sessions dedicated to overcoming the toughest of challenges across the drug discovery pipeline, grab your team and secure your pass today to accelerate your clinical proof of concept and kickstart your journey to the clinic.

Looking forward to seeing you in October!

Best wishes,

Cade Hildreth
Founder/President, BioInformant

Conference Hosted by
Hanson Wade
Event Guide | Pricing | Partner

---